The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to brelovitug (BJT-778) for the treatment of chronic hepatitis delta (CHD).

A revolutionary new treatment for breast cancer has shown the ability to eliminate small breast tumors and significantly ...

Penn Medicine is one of the first institutions to develop FDA-approved CAR T-cell therapies. This therapy is currently ...

Nuvalent, Inc. shares have fallen approximately 30% after promising updates on its two lead NSCLC candidates rallied the ...

Brelovitug has previously received Orphan and PRIME designation from the European Medicines Agency.

Scientists at The Hospital for Sick Children (SickKids) have identified a key gene that could lead to next-generation treatments for medulloblastoma, the most common malignant brain tumor in children.

Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage breakthrough neuropsychiatry ...

Innovent Biologics, Inc., announced that the Center for Drug Evaluation (CDE) of China's National Medical Products ...

What You Need to Know The global hydrogen water market is projected to grow from USD 2.5 billion in 2024 to USD 4.35 billion ...